Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhu, Shimiao ^a   Tang, Yang ^a   Li, Kai ^b   Shang, Zhiqun ^a   Jiang, Ning ^a   Nian, Xuewu ^a   Sun, Libin ^a   Niu, Yuanjie ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Third Central Hospital   (China)

Author keywords

Bacillus Calmette Gu rin; Combination therapy; Low dose; Maintenance therapy; Non muscle invasive bladder cancer; Prognosis

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; EPIRUBICIN; MITOMYCIN; ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CARCINOMA IN SITU; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEMATURIA; HUMAN; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SUPERFICIAL BLADDER CANCER; SUPERFICIAL CANCER; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; CARCINOMA, TRANSITIONAL CELL; COMPARATIVE STUDY; INTRAVESICAL DRUG ADMINISTRATION; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84879811751     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-332     Document Type: Article

References (47)

1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116(2):180-183.
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59(6):997-1008. 10.1016/j.eururo.2011.03.017, 21458150.
3. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004, 63(4):682-686. 686-687, 10.1016/j.urology.2003.11.049, 15072879.
4. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168(5):1964-1970. 10.1016/S0022-5347(05)64273-5, 12394686.
5. Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, Mori K, Kamimura N, Koie T, Yamato T, et al. Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology 2008, 71(6):1161-1165. 10.1016/j.urology.2007.11.080, 18279920.
6. Kumar A, Dubey D, Bansal P, Mandhani A, Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 2002, 168(5):2232-2235. 10.1016/S0022-5347(05)64361-3, 12394765.
7. Yalcinkaya F, Kamis L, Ozteke O, Gunlusoy B, Yigitbasi O, Unal S. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int Urol Nephrol 1998, 30(1):41-44. 10.1007/BF02550276, 9569110.
8. Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010, 57(3):410-429. 10.1016/j.eururo.2009.11.023, 19969411.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097. 10.1371/journal.pmed.1000097, 2707599, 19621072.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12. 10.1016/0197-2456(95)00134-4, 8721797.
11. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa Hospital Research Institute Web site 2012, [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp]. Accessed July 15, 2012.
12. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Levels of evidence and grades of recommendation 2012, Oxford Centre for Evidence-based Medicine Levels of Evidence, [http://www.cebm.net/index.aspx?o=1025]. Accessed July 15, 2012.
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8, 9921604.
14. Zhu S, Zhang H, Xie L, Chen J, Niu Y. Risk factors and prevention of inguinal hernia after radical prostatectomy: a systematic review and meta-analysis. J Urol 2013, 189(3):884-890. 10.1016/j.juro.2012.08.241, 23009871.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
16. Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S, Terai A, Nasu Y, et al. Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2011, 108(2):187-195. 10.1111/j.1464-410X.2010.09891.x, 21176079.
17. Okamura T, Akita H, Ando R, Ikegami Y, Naiki T, Kawai N, Tozawa K, Kohri K. Single monthly bacillus Calmette-Guerin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer. Int J Clin Oncol 2011, 17(5):477-481.
18. Koga H, Ozono S, Tsushima T, Tomita K, Horiguchi Y, Usami M, Hirao Y, Akaza H, Naito S. Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol 2010, 17(9):759-766. 10.1111/j.1442-2042.2010.02584.x, 20604814.
19. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough?. Cancer 2008, 113(4):710-716. 10.1002/cncr.23627, 18543328.
20. Andius P, Holmang S. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004, 93(7):980-984. 10.1111/j.1464-410X.2003.04764.x, 15142147.
21. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001, 165(5):1488-1491. 10.1016/S0022-5347(05)66333-1, 11342902.
22. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163(4):1124-1129. 10.1016/S0022-5347(05)67707-5, 10737480.
23. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WJ, Fair WR, Oettgen HF. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 1987, 5(3):441-449.
24. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987, 138(2):295-298.
25. Ojea A, Nogueira JL, Solsona E, Flores N, Gomez JM, Molina JR, Chantada V, Camacho JE, Pineiro LM, Rodriguez RH, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007, 52(5):1398-1406. 10.1016/j.eururo.2007.04.062, 17485161.
26. Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, Shimura S, Iwamura M, Baba S. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guerin for superficial bladder cancer recurrence. Int J Urol 2003, 10(4):183-189. 10.1046/j.0919-8172.2003.00607.x, 12657096.
27. Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 1995, 27(6):723-733. 10.1007/BF02552138, 8725038.
28. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013, 63(3):462-472. 10.1016/j.eururo.2012.10.039, 23141049.
29. Gulpinar O, Halilioglu OH, Gokce MI, Gogus C, Baltaci S. The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study. Int Braz J Urol 2012, 38(4):474-479.
30. Oosterlinck W, Kirkali Z, Sylvester R, Da SF, Busch C, Algaba F, Collette S, Bono A. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 2011, 59(3):438-446. 10.1016/j.eururo.2010.11.038, 21156335.
31. Badalato GM, Hruby G, Razmjoo M, McKiernan JM. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?. Can J Urol 2011, 18(5):5890-5895.
32. El Mohsen M, Shelbaia A, EG S. Sequential chemoimmunotherapy using mitomycin followed by Bacillus Calmette-Guerin (MCC + BCG) versus single-agent immunotherapy (bcg) for recurrent superficial bladder tumors. Uro Today Int J 2010, 3(3). [http://www.urotoday.com/UIJ/Archive/Volume-3/Issue-3-June-2010/sequential-chemoimmunotherapy-using-mitomycin-followed-by-bacillus-calmetteguerin-mcc-bcg-versus-singleagent-immunotherapy-bcg-for-recurrent-superficial-bladder.html].
33. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006, 7(1):43-51. 10.1016/S1470-2045(05)70472-1, 16389183.
34. Kaasinen E, Wijkstrom H, Malmstrom PU, Hellsten S, Duchek M, Mestad O, Rintala E. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 2003, 43(6):637-645. 10.1016/S0302-2838(03)00140-4, 12767365.
35. Jarvinen R, Kaasinen E, Rintala E, Group TF. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guerin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. Scand J Urol Nephrol 2012, 46(6):411-417. 10.3109/00365599.2012.694906, 22746387.
36. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998, 160(5):1668-1671. 1671-1672, 10.1016/S0022-5347(01)62377-2, 9783928.
37. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol 1996, 156(1):56-59. 59-60, 10.1016/S0022-5347(01)65936-6, 8648837.
38. Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008, 180(1):110-115. 10.1016/j.juro.2008.03.038, 18485394.
39. Tozawa K, Okamura T, Sasaki S, Kawai N, Ito Y, Hayashi Y, Kohri K. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin is not indicated for superficial bladder cancer. Urol Int 2001, 67(4):289-292. 10.1159/000051005, 11741130.
40. Bilen CY, Ozen H, Aki FT, Aygun C, Ekici S, Kendi S. Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol 2000, 7(6):206-209. 10.1046/j.1442-2042.2000.00176.x, 10843451.
41. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010, 184(5):1915-1919. 10.1016/j.juro.2010.06.147, 20846688.
42. Bazarbashi S, Raja MA, El SA, Ezzat A, Ibrahim E, Kattan S, Kardar A, Peracha A, Lindstedt E, Hanash K. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guerin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results. J Surg Oncol 2000, 74(3):181-184. 10.1002/1096-9098(200007)74:3<181::AID-JSO3>3.0.CO;2-F, 10951412.
43. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JJ, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178(6):2314-2330. 10.1016/j.juro.2007.09.003, 17993339.
44. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 1999, 162(4):2399-2405.
45. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999, 189(9):1451-1460. 10.1084/jem.189.9.1451, 2193058, 10224285.
46. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006, 24(4):344-348. 10.1016/j.urolonc.2005.11.026, 16818189.
47. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997, 350(9074):326-329. 10.1016/S0140-6736(97)02419-7, 9251637.